BRCA1 and neoplasm: In BRCA1 gene-deficient breast cancer, PARPi also upregulates PD-L1 expression on tumor cell surfaces by inactivating GSK3β, thereby inhibiting the activation of tumor-infiltrating T lymphocytes.